Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 LIBRETTO-432 clinical trial of ...

A cohort study examines whether the use of common medications was associated with worse outcomes in patients with lung cancer taking immunotherapy.

Eli Lilly’s oral targeted cancer therapy, Retevmo, has shown benefit as an adjunctive therapy in a Phase III trial in ...

This is a "landmark study" for cancer immunotherapy and circadian medicine, researcher say ...

When lung cancer treatment stops working, what happens next? New research reveals the answer may depend on how the cancer ...

Brain metastases are far from a niche concern; with 100,000 to 200,000 cases diagnosed annually in the US, the scale of the ...

The national survival rate for lung cancer has increased by 26% in the past 5 years, to 28.4% of all cases, according to a new report from the American Lung Association. Rates of preventive screening ...

Pennsylvania has seen improvement over the past five years in the diagnosis rate and survivability of lung cancer, but more can be done. These are among the trends examined in the American Lung ...

About a decade later, the U.S. Preventive Services Taskforce (USPSTF) issued updated guidelines recommending annual screening for lung cancer with low-dose CT for adults ages 50 to 80 years with a 20 ...

A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response ...